M-cell targeted delivery of recombinant hepatitis B surface antigen using cholera toxin B subunit conjugated bilosomes

International Journal of Pharmaceutics

Volumn 385, Issue 1-2, 2010, Pages 47-52

  Shukla, Anshuman ^a   Katare, O P ^a   Singh, Bhupinder ^a   Vyas, Suresh P ^b  

^a PANJAB UNIVERSITY   (India)

^b DR H S GOUR UNIVERSITY   (India)

Author keywords

CTB; HBsAg; M cells; Mucosal; Oral immunization; Vaccine

Indexed keywords

ALUMINUM POTASSIUM SULFATE; BILE SALT; BILOSOME; CHOLERA TOXIN B SUBUNIT; DRUG CARRIER; IMMUNOGLOBULIN G ANTIBODY; RECOMBINANT ANTIGEN; RECOMBINANT HEPATITIS B SURFACE ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; BAGG ALBINO MOUSE; BODY FLUID; CONTROLLED STUDY; DRUG ACTIVITY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMAGGLUTINATION TEST; HEPATITIS B; IMMUNIZATION; INTESTINE CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SERUM;

ADMINISTRATION, ORAL; ANIMALS; BILE ACIDS AND SALTS; CHEMISTRY, PHARMACEUTICAL; CHOLERA TOXIN; DRUG CARRIERS; DRUG STABILITY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HEXOSES; IMMUNITY, MUCOSAL; IMMUNOTOXINS; INJECTIONS, INTRAMUSCULAR; INTESTINAL MUCOSA; LIPIDS; MICE; MICE, INBRED BALB C; MICROSCOPY, FLUORESCENCE; PARTICLE SIZE; PEYER'S PATCHES; RECOMBINANT PROTEINS; STEARATES;

EID: 72449211710     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2009.10.027     Document Type: Article

References (48)

1. Bennett E., Mullen A.B., and Ferro V.A. Translational modifications to improve vaccine efficacy in an oral influenza vaccine. Methods (2009) 10.1016/j.ymeth.2009.04.015
2. Bernard G., Maike D.B., Jan W.S., Wil S., and Andre B. A comparison of natural and recombinant cholera toxin B subunit as stimulatory factors in intranasal immunization. Vaccine 15 (1997) 1110-1113
3. Borges O., Tavares J., Sousa A., Borchard G., Junginger H.E., and Cordeiro-da-Silva A. Evaluation of the immune response following a short oral vaccination schedule with hepatitis B antigen encapsulated into alginate-coated chitosan nanoparticles. Eur. J. Pharm. Sci. 32 (2007) 278-290
4. Brayden D.J., and O'Mahony D.J. Novel oral drug delivery gateways for biotechnology products: polypeptides and vaccines. Pharm. Sci. Tech. Today 1 (1998) 291-299
5. Chen H., Torchilin V., and Langer R. Lectin-bearing polymerized liposomes as potential oral vaccine carriers. Pharm. Res. 13 (1996) 1378-1383
6. Chen L., Liu F., Fan X., Gao J., Chen N., Wong T., Wu J., and Wen S.W. Detection of hepatitis B surface antigen, hepatitis B core antigen, and hepatitis B virus DNA in parotid tissues. Int. J. Infect. Dis. 13 (2009) 20-23
7. Clark M.A., Blair H., Liang L., Brey R.N., Brayden D., and Hirst B.H. Targeting polymerised liposome vaccine carriers to intestinal M cells. Vaccine 20 (2001) 208-217
8. Clark M.A., Jepson M.A., and Hirst B.H. Exploiting M cells for drug and vaccine delivery. Adv. Drug Deliv. Rev. 50 (2001) 81-106
9. Conacher M., Alexander J., and Brewer J.M. Oral immunisation with peptide and protein antigens by formulation in lipid vesicles incorporating bile salts (bilosomes). Vaccine 19 (2001) 2965-2974
10. Dertzbaugh M.T., and Elson C.O. Comparative effectiveness of the cholera toxin B subunit and alkaline phosphatase as carriers for oral vaccines. Infect. Immun. 61 (1993) 48-55
11. DiBiase M.D., and Morrel E.M. Oral delivery of microencapsulated proteins. Pharm. Biotechnol. 10 (1997) 255-288
12. Elson C.O., Ealding W., and Lefkowitz J. A lavage technique following repeated measurement of IgA antibody in mouse intestinal secretions. J. Immunol. Methods 67 (1984) 101-108
13. Ermak T.H., and Giannasca P.J. Microparticle targeting to M cells. Adv. Drug Deliv. Rev. 34 (1998) 261-283
14. Frey A., Giannasca K.T., Weltzin R., Giannasca P.J., Regggio H., Lencer W.I., and Neutra M.R. Role of glycocalyx in regulating access of microparticles to apical plasma membranes of intestinal epithelial cells: implications for microbial attachment and oral vaccine targeting. J. Exp. Med. 184 (1996) 1045-1059
15. Fry D.W., White J.C., and Goldman I.D. Rapid separation of low molecular weight solutes from liposomes without dilution. Anal. Biochem. 90 (1978) 809-815
16. Gao Y., Ma Y., Li M., Cheng T., Li S.W., Zhang J., and Xia N.S. Oral immunization of animals with transgenic cherry tomatillo expressing HBsAg. World J. Gastroenterol. 9 (2003) 996-1002
17. Gupta P.N., Khatri K., Goyal A.K., Mishra N., and Vyas S.P. M-cell targeted biodegradable PLGA nanoparticles for oral immunization against hepatitis B. J. Drug Target. 15 (2007) 701-713
18. Harokopakis E., Childers N.K., Michalek S.M., Zhang S.S., and Tomasi M. Conjugation of cholera toxin or its B subunit to liposomes for targeted delivery of antigens. J. Immunol. Methods 185 (1995) 31-42
19. He X.W., Wang F., Jiang L., Li J., Liu S.K., Xiao Z.Y., Jin X.Q., Zhang Y.N., He Y., Li K., Guo Y.J., and Sun S.H. Induction of mucosal and systemic immune response by single-dose oral immunization with biodegradable microparticles containing DNA encoding HBsAg. J. Gen. Virol. 86 (2005) 601-610
20. Hilleman M.R. Critical overview and outlook: pathogenesis, prevention and treatment of hepatitis and hepatocarcinoma caused by hepatitis B virus. Vaccine 21 (2003) 4626-4649
21. Hillery A.M. Microparticulate delivery systems: potential drug/vaccine carriers via mucosal routes. Pharm. Sci. Tech. Today 1 (1998) 69-75
22. Holmgren J., Lycke N., and Czerkinsky C. Cholera toxin and cholera B subunit as oral-mucosal adjuvant and antigen vector systems. Vaccine 11 (1993) 1179-1184
23. Isaka M., Yasuda Y., Mizokami M., Kozuka S., Taniguchi T., Matano K., Maeyama J., Mizuno K., Morokuma K., Goto N., and Tochikubo K. Mucosal immunization against hepatitis B virus by intranasal co-administration of recombinant hepatitis B surface antigen and recombinant cholera toxin B subunit as an adjuvant. Vaccine 19 (2001) 1460-1466
24. Jaganathan K.S., and Vyas S.P. Strong systemic and mucosal immune responses to surface-modified PLGA microspheres containing recombinant hepatitis B antigen administered intranasally. Vaccine 24 (2006) 4201-4211
25. Kapusta J., Modelska A., Figlerowicz M., Pniewski T., Letellier M., Lisowa O., Yusibov V., Koprowski H., Plucienniczak A., and Legocki A.B. A plant-derived edible vaccine against hepatitis B virus. FASEB J. 13 (1999) 1796-1799
26. Kapusta J., Modelska A., Pniewski T., Figlerowicz M., Jankowski K., Lisowa O., Plucienniczak A., Koprowski H., and Legocki A.B. Oral immunization of human with transgenic lettuce expressing hepatitis B surface antigen. Adv. Exp. Med. Biol. 495 (2001) 299-303
27. Kong Q., Richter L., Yang Y.F., Arntzen C.J., Mason H.S., and Thanavala Y. Oral immunization with hepatitis B surface antigen expressed in transgenic plants. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 11539-11544
28. Lehr C.M. Bioadhesion technologies for the delivery of peptide and protein drugs to the gastrointestinal tract. Crit. Rev. Ther. Drug Carrier Syst. 11 (1994) 119-160
29. Magistris M.T.D. Mucosal delivery of vaccine antigens and its advantages in pediatrics. Adv. Drug Deliv. Rev. 58 (2006) 52-67
30. Mann J.F., Acevedo R., Campo J.D., Pérez O., and Ferro V.A. Delivery systems: a vaccine strategy for overcoming mucosal tolerance?. Expert. Rev. Vaccines 8 (2009) 103-112
31. Mann J.F., Ferro V.A., Mullen A.B., Tetley L., Mullen M., Carter K.C., Alexander J., and Stimson W.H. Optimization of a lipid based oral delivery system containing A/Panama influenza haemagglutinin. Vaccine 22 (2004) 2425-2429
32. Mann J.F., Scales H.E., Shakir E., Alexander J.A., Carter K.C., Mullen A.B., and Ferro V.A. Oral delivery of tetanus toxoid using vesicles containing bile salts (bilosomes) induces significant systemic and mucosal immunity. Methods 38 (2006) 90-95
33. Myschik J., Rades T., and Hook S. Advances in lipid-based subunit vaccine formulations. Curr. Immunol. Rev. 5 (2009) 42-48
34. McClean S., Meehan E., O'Malley D., Clarke N., Ramtoola Z., and Brayden D. Binding and uptake of biodegradable poly-dl-lactide micro- and nanoparticles in intestinal epithelia. Eur. J. Pharm. Sci. 6 (1998) 153-163
35. McGhee J.R., Mestecky J., Dertzbaugh M.T., Eldridge J.H., Hirasawa M., and Kiyono H. The mucosal immune system: from fundamental concepts to vaccine development. Vaccine 10 (1992) 75-88
36. Owen R.L., Pierce N.F., Apple R.T., and Cray Jr. W.C. M cell transportation of Vibrio cholerae from intestinal lumen into Peyer's patches: a mechanism for antigen sampling and for microbial transepithelial migration. J. Infect. Dis. 153 (1986) 1108-1118
37. Rajkannan R., Dhanaraju M.D., Gopinath D., Selvaraj D., and Jayakumar R. Development of hepatitis B oral vaccine using B-cell epitope loaded PLG microparticles. Vaccine 24 (2006) 5149-5157
38. Ryan E.J., Daly L.M., and Mills K.H.G. Immunomodulators and delivery systems for vaccination by mucosal routes. Trends Biotechnol. 19 (2001) 293-304
39. Sanchez Y., Matiu I.I., Dreesman G.R., Kramp W., Six H.R., Hollinger B., and Melnick J.L. Humoral and cellular immunity to hepatitis B virus-derived antigens: comparative activity of Freund complete adjuvant, alum and liposomes. Infect. Immun. 30 (1980) 728-733
40. Shalaby W.S.W. Development of oral vaccines to stimulate mucosal and systemic immunity: barriers and novel strategies. Clin. Immunol. Immunopathol. 74 (1995) 127-134
41. Shukla A., Khatri K., Gupta P.N., Goyal A.K., Mehta A., and Vyas S.P. Oral immunization against hepatitis B using bile salt stabilized vesicles (bilosomes). J. Pharm. Pharm. Sci. 11 (2008) 59-66
42. Simerska P., Moyle P.M., Olive C., and Toth I. Oral vaccine delivery-new strategies and technologies. Curr. Drug Deliv. 6 (2009) 347-358
43. Singh M., and O'Hagan D.T. The preparation and characterization of polymeric antigen delivery systems for oral administration. Adv. Drug Deliv. Rev. 34 (1998) 285-304
44. Singh P., Prabakaran D., Jain S., Mishra V., Jaganathan K.S., and Vyas S.P. Cholera toxin B subunit conjugated bile salt stabilized vesicles (bilosomes) for oral immunization. Int. J. Pharm. 278 (2004) 379-390
45. Thanavala Y., Mahoney M., Pal S., Scott A., Richter L., Natarajan N., Goodwin P., Arntzen C.J., and Mason H.S. Immunogenicity in humans of an edible vaccine for hepatitis B. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 3378-3382
46. Thanavala Y., and Lugade A.A. Oral transgenic plant-based vaccine for hepatitis B. Immunol. Res. (2009) 10.1007/s12026-009-8127-4
47. Walker R.I. New strategies for using mucosal vaccination to achieve more effective immunization. Vaccine 12 (1994) 387-400
48. Wilding I.R., Davis S.S., and O'Hagan D.T. Targeting of drugs and vaccines to gut. Pharm. Ther. 62 (1994) 97-124